PAX8 and carcinoma: Overall, therefore a cytokeratin/EMA-focal and PAX8/ER/E-cadherin-negative immunoprofile, along with loss of BRG-1 or INI-1 expression would favor undifferentiated or dedifferentiated carcinoma over grade 3 endometrioid carcinoma (Box 3).